- Home
- LEGH vs CRGX Comparison
LEGH vs CRGX Comparison
Compare LEGH & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- CRGX
- Stock Information
- Founded
- LEGH 2005
- CRGX 2021
- Country
- LEGH United States
- CRGX United States
- Employees
- LEGH N/A
- CRGX N/A
- Industry
- LEGH Homebuilding
- CRGX
- Sector
- LEGH Consumer Discretionary
- CRGX
- Exchange
- LEGH Nasdaq
- CRGX Nasdaq
- Market Cap
- LEGH 588.8M
- CRGX 190.0M
- IPO Year
- LEGH 2018
- CRGX 2023
- Fundamental
- Price
- LEGH $23.25
- CRGX $4.59
- Analyst Decision
- LEGH Strong Buy
- CRGX Hold
- Analyst Count
- LEGH 2
- CRGX 7
- Target Price
- LEGH $29.00
- CRGX $5.33
- AVG Volume (30 Days)
- LEGH 102.7K
- CRGX 1.9M
- Earning Date
- LEGH 08-07-2025
- CRGX 08-11-2025
- Dividend Yield
- LEGH N/A
- CRGX N/A
- EPS Growth
- LEGH 8.04
- CRGX N/A
- EPS
- LEGH 2.29
- CRGX N/A
- Revenue
- LEGH $176,618,000.00
- CRGX N/A
- Revenue This Year
- LEGH N/A
- CRGX $57.81
- Revenue Next Year
- LEGH $8.23
- CRGX N/A
- P/E Ratio
- LEGH $10.24
- CRGX N/A
- Revenue Growth
- LEGH N/A
- CRGX N/A
- 52 Week Low
- LEGH $21.58
- CRGX $3.00
- 52 Week High
- LEGH $29.31
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- LEGH 55.84
- CRGX 61.56
- Support Level
- LEGH $23.25
- CRGX $4.32
- Resistance Level
- LEGH $24.20
- CRGX $4.63
- Average True Range (ATR)
- LEGH 0.66
- CRGX 0.16
- MACD
- LEGH 0.14
- CRGX 0.04
- Stochastic Oscillator
- LEGH 69.87
- CRGX 76.44
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.